RxDoctor Payments Data

Matthew Marcarian, MD

Internal Medicine · Dearborn Heights, MINPI 1891773677

Payments from drug & device makers

$4,216in general payments, 2019–2025

Across 255 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$657
  • Lilly USA, LLC$654
  • Pfizer$518
  • Boehringer Ingelheim$450
  • AstraZeneca$267
  • AbbVie$194
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,15198%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,216 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$104,024
Medicare patients
222
Services billed
1,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$106,857
EliquisApixaban95$89,750
JardianceEmpagliflozin59$87,058
OzempicSemaglutide28$42,830
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$31,543
XareltoRivaroxaban17$22,591
JanuviaSitagliptin Phosphate16$21,124
LinzessLinaclotide26$20,125
TrulancePlecanatide15$13,248
FarxigaDapagliflozin Propanediol11$12,609
MultaqDronedarone Hcl12$10,656
Breo ElliptaFluticasone/Vilanterol12$10,582
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$7,748
Atorvastatin Calcium483$6,146
MyrbetriqMirabegron12$5,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$654$106,85797 claims
PfizerEliquis$518$89,75095 claims
Boehringer IngelheimJardiance$450$87,05859 claims
Novo NordiskOzempic, Novolog$657$44,01743 claims
GSKTrelegy Ellipta, Breo Ellipta$186$42,12547 claims
Johnson & JohnsonXarelto$163$22,59117 claims
MerckJanuvia$85$21,12416 claims
AbbVieLinzess$194$20,12526 claims
AstraZenecaFarxiga, Brilinta$267$17,27822 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$135$13,24815 claims
Sanofi-aventis U.S. LLCMultaq$18$10,65612 claims
Astellas Pharma US IncMyrbetriq$154$5,47912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →